Report
Olga Smolentseva

HEIDELBERG PHARMA (BUY, TP EUR12) | Setbacks in BCMA-targeting space leave more room for HDP-101

HEIDELBERG PHARMA (BUY, TP EUR12) | Setbacks in BCMA-targeting space leave more room for HDP-101
Underlying
Heidelberg Pharma AG

Wilex is a biopharmaceutical company focused on oncology and antibodies. The parent company WILEX AG no longer pursues clinical development activities in Munich, instead acting exclusively as a holding company. Operation concentrate on the research and development activities of the subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma workes with the toxin Amanitin and an ADC technology with the goal of coupling this highly effective agent with various antibodies to make it usable for treating cancer. This innovative technology platform is progressively being developed for therapeutic antibody drug conjugates for use in proprietary projects and partnerships.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch